TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 40 mg
Description: IPX056 Extended Release capsule containing 40 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 40 mg
Description: IPX056 Extended Release capsule containing 40 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: Encapsulated Baclofen 20 mg
Description: Baclofen 20mg tablet was encapsulated for blinding.

Intervention type: DRUG
Group type: OTHER
Intervention: Encapsulated Baclofen 20 mg
Description: Baclofen 20mg tablet was encapsulated for blinding.

Intervention type: DRUG
Group type: OTHER
Intervention: Encapsulated Baclofen 20 mg
Description: Baclofen 20mg tablet was encapsulated for blinding.

Intervention type: DRUG
Group type: OTHER
Intervention: Encapsulated Baclofen 20 mg
Description: Baclofen 20mg tablet was encapsulated for blinding.
Study: NCT02013765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Intrathecal/ Intravenous/ Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: Intrathecal/ Intravenous/ Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Daunorubicin
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Intravenous
Study: NCT03190382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Support Tool
Description: Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
Study: NCT00680407

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (5 pills, three times daily) for 48-50 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin 700 mg
Description: 700 mg dose (5 pills, three times daily) for 48-50 week treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin 420 mg
Description: 420 mg dose (5 pills, three times daily) for 48-50 week treatment period
Study: NCT01692704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
Description: Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.~Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.~Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications.
Study: NCT01821781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
Description: Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Intravenous/ Subcutaneous injection
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Baclofen Tablet
Description: Placebo capsule encapsulated placebo Baclofen tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Baclofen Tablet
Description: Placebo capsule encapsulated placebo Baclofen tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Baclofen Tablet
Description: Placebo capsule encapsulated placebo Baclofen tablet
Study: NCT03815071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ips-nsc cells
Description: Total dose of ips-nsc cells will be administered at day0.
Study: NCT01323439

Intervention type: DEVICE
Intervention: Axium™ MicroFX™ PGLA COILS
Description: Axium™ MicroFX™ PGLA COILS to treat aneurysms
Study: NCT01705457

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: vitamin A
Description: 25000 IU/day vitamin A for 6 months~1 Cap/Day~1 cap placebo/day for 6 month

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 10 mg
Description: IPX056 Extended Release capsule containing 10 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 10 mg
Description: IPX056 Extended Release capsule containing 10 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 10 mg
Description: IPX056 Extended Release capsule containing 10 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 10 mg
Description: IPX056 Extended Release capsule containing 10 mg baclofen
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 30 mg
Description: IPX056 Extended Release capsule containing 30 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 30 mg
Description: IPX056 Extended Release capsule containing 30 mg baclofen
Study: NCT03450551

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block, Herbst, Frog distalising appliance
Description: To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin Block, Herbst, Frog distalising appliance
Description: To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Block, Herbst, Frog distalising appliance
Description: To study which of the three orthodontic appliances does achieve the best clinical progress, produce least discomfort to the patient, minimize the time taken for completion of treatment and maximize compliance.
Study: NCT04018027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 0.25 mg
Description: Oral difelikefalin 0.25 mg administered twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 0.5 mg
Description: Oral difelikefalin 0.5 mg administered twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 1.0 mg
Description: Oral difelikefalin 1.0 mg administered twice daily
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Intravenous/ Subcutaneous injection
Study: NCT00488839

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 35 mg
Description: IPX056 Extended Release capsule containing 35 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 35 mg
Description: IPX056 Extended Release capsule containing 35 mg baclofen

Intervention type: DRUG
Group type: OTHER
Intervention: IPX056 35 mg
Description: IPX056 Extended Release capsule containing 35 mg baclofen
Study: NCT04018027

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo administered twice daily
Study: NCT01519206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System Treatment
Description: Focused ultrasound energy delivered below the surface of the skin.
Study: NCT04169841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib, durvalumab, tremelimumab
Description: STEP 1:~Olaparib 300 mg BID during 8 weeks. Olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water. The tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib tablets can be taken with or without food~STEP 2:~Olaparib 300 mg during 4 months as per same requirement as below. Durvalumab 1500 mg plus tremelimumab 75 mg via IV infusion Q4W, starting on Week 0, for up to a maximum of 4 doses followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination and in response or stable after prior molecular target therapy by olaparib based on molecular sequencing.
Study: NCT02894645

Intervention type: DRUG
Group type: OTHER
Intervention: Cytarabine
Description: Intravenous/ Subcutaneous injection

Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: 6-Mercaptopurine
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Thioguanine
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Thioguanine
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Thioguanine
Description: Oral

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Intravenous

Intervention type: DRUG
Group type: OTHER
Intervention: Imatinib
Description: Oral (For BCR-ABL ALL only)
Study: NCT02748304

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: just follow up

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: sorafenib 400mg bid po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib
Description: sorafenib 400mg bid po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100mg qd po
Study: NCT04269369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: The aim of this study is to investigate if the systematic implementation of pre-emptive geno- and phenotyping, and therefore a dose reduction based on the French guidelines and the literature during the first month of treatment, reduces grade 3 or greater toxicity in patients treated with 5-FU or capecitabine. Therefore a dosing table was obtained by combining the results of the study by Henricks et al., Launay et al. and Yang et al. and the recommendations from the French HAS guideline. The treatment schedule then will be discussed by the team of doctors and paramedics at the weekly MOC (multidisciplinary cancer consultation). Complementary, the pharmacist provides dose advice with regard to the start of 5-FU or capecitabine treatment.~In a subgroup, the group of patients with genotype wild type and phenotype intermediate metabolizer, a comparison will be made between group A with dosage according to French guidelines and group B with dosage according to literature.
Study: NCT02127151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMN 673
Description: Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
Study: NCT04762160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Study Drug

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Partner Drug
Study: NCT03321318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK-R215
Description: Investigational product is prescribed to all ofrandomized subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AK-R215
Description: Investigational product is prescribed to all ofrandomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene 20 mg
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 800IU
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 800IU
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT04181021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Clarification and Attitudes Transformation (VCAT) Workshop
Description: VCAT is a participatory workshop aimed to provide accurate information about abortion and family planning and space to engage in critical self-reflection, provoke dialogue on beliefs, values and professional ethics and responsibilities around providing abortion and contraceptive care, and provide a deeper understanding of the range of circumstances in which women seek abortion and contraception.
Study: NCT01344421

Intervention type: PROCEDURE
Intervention: Minimally invasive approach for Periacetabular osteotomy
Description: A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
Study: NCT01734005

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red Ginseng
Description: Red Ginseng (1.4g/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.4g/day)
Study: NCT03691519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 treatment
Description: Patient in the treatment comparative arm will consume 3- 1g softgel vegetarian capsules of DHA-O per day as a single dose for 36 months; each 1g capsule of DHA-0 providing 324 mg DHA and 185 mg EPA (total daily DHA+EPA dose = 1.53 g/day).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The appearance and taste of the placebo will be similar to those of the active ingredient. Placebo capsules contained a 1:1 ratio of corn oil and soy oil.~36 months consisting of a 18-month placebo-controlled period followed by a 18-month open-label extension period wherein all participants will receive active treatment. Active treatment consists of 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day).~For the 18 months placebo-controlled period (n=200/arm): 1.53 g /day dose of DHA-0 (972 mg /day DHA + 555 mg /day EPA; 3 caps /day) or placebo (3 similar pills /day).
Study: NCT03327259

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activity Planning
Description: The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Planning
Description: The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist Guided Activity Practice
Description: The therapist will work with the participant to plan and carry out a brief in-vivo version of their goal/target activity. The therapist will guide the participant through the activity for approximately 15 minutes.
Study: NCT04111289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: -Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)
Description: * After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: -Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)
Description: * After consenting for primary PCI ,the patient will be assigned to one arm ( either upstream high bolus dose IV before going to cath lab or selective downstream administration according to operator discretion )~* Administration of tirofiban (25 ug/kg bolus and 0.15 ug/kg/min maintenance infusion)~* Randomization will be performed by Microsoft Excel where random order will be generated for the study population
Study: NCT00691444

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Subjects will be given up to 0.5 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Subjects will be given up to 10 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Subjects will be given up to 20 mg daily.~0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns).
Study: NCT02256618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood cells
Description: Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
Study: NCT02841839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Study: NCT01831661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Hydrochloride Extended-Release Tablets USP 750 mg
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride Extended-Release Tablets USP 750 mg
Description: Metformin Hydrochloride Extended-Release Tablets 750 mg once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLUCOPHAGE®XR
Description: GLUCOPHAGE®XR 750 mg once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLUCOPHAGE®XR
Description: GLUCOPHAGE®XR 750 mg once a day
Study: NCT00882518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)
Description: 200 mg or 300 mg, oral, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpromazine
Description: 50 mg, oral, double dose
Study: NCT03364725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir-pibrentasvir
Description: Glecaprevir-pibrentasvir will be dispensed to 30 patients recently detoxed off heroin in an acute detox center.
Study: NCT01227473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based diabetes prevention education group
Description: The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional diabetes prevention education group
Description: The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
Study: NCT01884246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-care CVD risk reduction
Description: A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral to primary care provider for CVD risk management
Description: The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to primary care provider for CVD risk management
Description: The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.